No phaseActive, not recruitingGeroscience intervention
Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans (NR-VET)
- Sponsor
- VA Office of Research and Development (US federal)
- Enrollment
- 74 enrolled
- Conditions
- Sarcopenia; Nicotinamide Adenine Dinucleotide Concentration; Muscle Quality and NAD+ Content
- Interventions
- Nicotinamide Riboside; Placebo
- Ages
- older adults
- Registry
- NCT04691986
Full record on ClinicalTrials.gov
From the registry
Frailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality. Nicotinamide adenine dinucleotide (NAD) is a critical co-factor needed for many cellular processes. The natural levels of NAD decline aging and this has been linked to physical performance decline in animals. Human trials have demonstrated that nicotinamide riboside (NR), a form of vitamin B3, is safe and effectively increases NAD+ levels. In animal studies, NR improves treadmill performance and muscle quality. Here the investigators propose a double-blind randomized control trial to assess the benefits of NR supplementation on human muscle function and physiology. The investigators anticipate the research findings will support the use of this nutritional supplement to improve the health of Veterans during aging.
Primary outcomes
- Sub-maximal oxygen uptake test (VO2max)
- Muscle strength
- Gait speed
History
Study completion expected
Last registry update
Primary completion
Started
Registered
In the news
TrialsDeutsches Ärzteblatt (opens Deutsches Ärzteblatt in a new tab)
Nicotinamide riboside shows no benefit in 410-person phase 3 trial for early Parkinson’s
Researchers report the yearlong, double-blind, placebo-controlled NOPARK trial in JAMA; it ran at 11 Norwegian centers.
TrialsMedical Xpress (opens Medical Xpress in a new tab)
Nicotinamide riboside slightly worsens early Parkinson’s scores in 410-person phase 3 trial
Researchers report a 2.72-point adjusted MDS-UPDRS difference favoring placebo after 52 weeks at 500 mg twice daily, statistically significant but below the clinical-importance threshold.
Also in JAMA (opens JAMA in a new tab), famtimes.co.kr (opens famtimes.co.kr in a new tab), N+1 (opens N+1 in a new tab), mdtoday.co.kr (opens mdtoday.co.kr in a new tab)

